Trial Profile

Pilot Study of HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 May 2026 According to a Soligenix media release, data from this trial were published in the journal of Oncology and Therapy.
23 Mar 2026 According to a Soligenix media release, data from this trial will be presented at the US Cutaneous Lymphoma Consortium Annual Workshop 2026 by Ellen Kim which precedes the American Academy of Dermatology (AAD) Annual Meeting.
19 Mar 2026 According to Soligenix media release, a summary of all the clinical trials completed to date evaluating HyBryte (synthetic hypericin) as a treatment for cutaneous T-cell lymphoma (CTCL) has been published in the peer-reviewed medical journal Expert Opinion on Investigational Drugs.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com